Toward inflammation-free therapeutics in alzheimer’s disease

Toward inflammation-free therapeutics in alzheimer’s disease

Play all audios:

Loading...

An engineered fusion protein exploits the efferocytosis pathway to clear amyloid-β (Aβ) from the brain without eliciting the severe inflammatory adverse effects associated with Aβ-targeting


antibody-based immunotherapies. In mouse models of Alzheimer’s disease, this approach induced robust clearance of Aβ without inflammation, improved synapse protection, and decreased brain


microhemorrhage, which result in superior behavioral recovery. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS


OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Learn


more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to


full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our


FAQs * Contact customer support REFERENCES * Busche, M. A. & Hyman, B. T. Synergy between amyloid-beta and tau in Alzheimer’s disease. _Nat. Neurosci._ 23, 1183–1193 (2020). A REVIEW


ARTICLE THAT PRESENTS THE COMPLEX INTERACTION BETWEEN AΒ AND TAU IN AD PATHOGENESIS. Article  CAS  Google Scholar  * Sevigny, J. et al. The antibody aducanumab reduces Abeta plaques in


Alzheimer’s disease. _Nature_ 537, 50–56 (2016). A PAPER THAT REPORTS THE EFFICACY AND SAFETY DATA FROM A PHASE 1B RANDOMIZED TRIAL OF ADUCANUMAB. Article  CAS  Google Scholar  * Fuller, J.


P., Stavenhagen, J. B. & Teeling, J. L. New roles for Fc receptors in neurodegeneration—the impact on immunotherapy for Alzheimer’s disease. _Front. Neurosci._ 8, 235 (2014). A REVIEW


ARTICLE THAT SUGGESTS THAT ACTIVATION OF INFLAMMATORY FCRS IN THE CENTRAL NERVOUS SYSTEM MAY HAVE HARMFUL CONSEQUENCES. Article  Google Scholar  * Doran, A. C., Yurdagul, A. Jr. & Tabas,


I. Efferocytosis in health and disease. _Nat. Rev. Immunol._ 20, 254–267 (2020). A REVIEW ARTICLE THAT PRESENTS HOW PHAGOCYTES TAKE UP AND PROCESS APOPTOTIC CELLS. Article  CAS  Google


Scholar  * Lemke, G. Biology of the TAM receptors. _Cold Spring Harb. Perspect. Biol._ 5, a009076 (2013). A REVIEW ARTICLE THAT PRESENTS HOW TAM RECEPTOR–LIGAND SIGNALING CONTROLS THE INNATE


IMMUNE RESPONSE. Article  Google Scholar  Download references ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps


and institutional affiliations. THIS IS A SUMMARY OF: Jung, H. et al. Anti-inflammatory clearance of amyloid-β by a chimeric Gas6 fusion protein. _Nat. Med_.


https://doi.org/10.1038/s41591-022-01926-9 (2022). RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Toward inflammation-free therapeutics in Alzheimer’s


disease. _Nat Med_ 28, 1765–1766 (2022). https://doi.org/10.1038/s41591-022-01972-3 Download citation * Published: 08 September 2022 * Issue Date: September 2022 * DOI:


https://doi.org/10.1038/s41591-022-01972-3 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not


currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative